Montaser Shaheen, M.D.
NOTE : If you're an existing patient, please connect via MyChart
About Montaser Shaheen, M.D.
Monte Shaheen, MD, is a professor of oncology at the University of Texas Health Science Center San Antonio and the director of the immunotherapy program at Mays Cancer Center. He is board certified in both hematology and oncology, focusing on melanoma and other cutaneous cancers.
Dr. Shaheen has extensive experience in treating melanoma and other skin cancers. He was part of the team that conducted initial work on the revolutionary immunotherapy combination of ipilimumab and nivolumab for the treatment of advanced melanoma. This regimen changed the predicted outcome of this disease from being uniformly lethal into a curable disease for a good portion of patients. He has also contributed to the approval of adjuvant immunotherapy for melanoma and the introduction of novel checkpoint inhibitors such as the new lag3 antibody relatlimab. Most recently, he contributed to the efforts that established neo-adjuvant immunotherapy as a potential new standard of care for locally advanced melanoma cases.
Dr. Shaheen is a physician-scientist with clinical and laboratory research efforts. His lab conducted research in carcinogenesis, genome instability and the ubiquitin pathway. Dr. Shaheen obtained his MD from Damascus University in Syria and completed his fellowship in hematology and oncology at Indiana University School of Medicine. Dr. Shaheen’s care philosophy is delivering comprehensive and expert care in collaboration with his patients.
- Professor, Oncology, University of Texas Health Science Center San Antonio
- Director, Melanoma and Translational Immunotherapy, Mays Cancer Center
- American board of Medical Oncology
- American board of Hematology/Oncology
- American board of Internal Medicine
- Medical School: Damascus University, Damascus, Syria
- Residency: Southern Illinois University School, Carbondale, Illinois
- Fellowship: Indiana University, Bloomington, Indiana
- Locations & Contact
Research & Publications
Research & Publications
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003272. PubMed PMID: 34599031; PubMed Central PMCID: PMC8488725.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PubMed PMID: 34986285
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, Patel V, Shaheen M, Bendell J, Fan AC, Gartrell BA, Goodman OB, Nikolinakos PG, Kalebasty AR, Zakharia Y, Zhang Z, Parmar H, Akella L, Orford K, Tan
Clin Cancer Res. 2022 Aug 2;28(15):3248-3255. doi: 10.1158/1078-0432.CCR-22-0061. PubMed PMID: 35576438
View All Research & Publications
- Clinical Trials